Reconceptualizing medication adherence: Six phases of dynamic adherence

Harvard Review of Psychiatry

Volumn 19, Issue 4, 2011, Pages 177-189

  Gearing, Robin E ^a   Townsend, Lisa ^b   MacKenzie, Michael ^a   Charach, Alice ^c  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b YORK UNIVERSITY   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Medication adherence; Mental illness; Patient provider relationship; Treatment compliance

Indexed keywords

NEUROLEPTIC AGENT;

ATTITUDE TO MENTAL ILLNESS; COMMUNICATION SKILL; CONSUMER ATTITUDE; COST BENEFIT ANALYSIS; DOCTOR PATIENT RELATION; DRUG COST; DRUG MARKETING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYNAMIC ADHERENCE; DYSPHORIA; HEALTH CARE POLICY; HEALTH STATUS; HUMAN; INFORMED CONSENT; MENTAL DISEASE; MENTAL HEALTH CARE; PATIENT AUTONOMY; PATIENT COMPLIANCE; PATIENT DECISION MAKING; PATIENT PARTICIPATION; PATIENT PREFERENCE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; REVIEW; STATISTICAL MODEL; TREATMENT OUTCOME; TREATMENT REFUSAL; UNSPECIFIED SIDE EFFECT;

DRUG COSTS; FINANCING, PERSONAL; HUMANS; MEDICATION ADHERENCE; MENTAL DISORDERS; MODELS, PSYCHOLOGICAL; PATIENT ACCEPTANCE OF HEALTH CARE; PHYSICIAN-PATIENT RELATIONS; PSYCHOTROPIC DRUGS; TREATMENT REFUSAL;

EID: 79960970361     PISSN: 10673229     EISSN: 14657309     Source Type: Journal    
DOI: 10.3109/10673229.2011.602560     Document Type: Review

References (92)

1. Gearing RE, Mian IA, Sholonsky A, et al. Developing a riskmodel of time to first-relapse for children and adolescents diagnosed with psychotic disorders ormood disorders with psychotic features J Nerv Ment Dis 2009;197:6-14.
2. National Council on Patient Information and Education. Children and medicines, Bethesda, MD: NCPIE, 1989.
3. Grahl C. Improving compliance: solving a $100 billion problem. Managed Health Care 1994:11-3.
4. Levensky ER. Nonadherence to treatment. In: Fisher ER, ODonohue WT, eds. Practitioners guide to evidence-based psychotherapy. New York: Springer, 2006.
5. Mental health: a report of the surgeon general: executive summary. Rockville, MD: Dept. of Health and Human Services, U.S. Public Health Service, 1999.
6. Gearing RE, Mian I, Charach A. Promoting adherence with children and adolescents with psychosis. Child Adol Psychopharm News 2008;13(1):5-9.
7. Haynes RB, McDonald H, Garg AXM, P. Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev 2002;(2):CD000011.
8. Kyngas HA, Skaar-Chandler CA, Duffy ME. The development of an instrument to measure the compliance of adolescents with a chronic disease. J Adv Nurs 2000;32:1499-506.
9. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97. (Pubitemid 41127293)
10. Cleemput I, Kesteloot K, DeGeest S. A review of the literature on the economics of noncompliance. Room for methodological improvement. Health Policy 2002;59:65-94. (Pubitemid 34098770)
11. Donovan J. Patient decision making: the missing ingredient in compliance research. INT J Tech Asst Health Care 1995;11:443-55.
12. Roberson MH. The meaning of compliance: patient perspectives. Qual Health Res 1992;2:7-26.
13. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008;(4):CD000011.
14. Novick D, Haro JM, Suarez D, Perez V, Dittmann RW, Haddad PM. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res 2010;176:109-13.
15. Velligan DI, Lam YF, Glahn DC, et al. Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophrenia Bull 2006;32:724-42. (Pubitemid 44412860)
16. MillerWR. Motivation for treatment: a review with special emphasis on alcoholism. Psychol Bull 1985;98:84-107.
17. Prochaska JO, DiClemente CC, Norcross JC. In search of how people change: applications to addictive behaviors. Am Psychol 1992;47:1102-14.
18. DiClemente CC, Nidecker M, Bellack AS. Motivation and the stages of change among individuals with severe mental illness and substance abuse disorders. J Subst Abuse Treat 2008;34:25-35. (Pubitemid 350225650)
19. Karter AJ, Parker MM, Moffet HH, Ahmed AT, Schmittdiel JA, Selby JV. New prescription medication gaps: a comprehensive measure of adherence to new prescriptions. Health Ser Res 2009;44:1640-61.
20. Shah NR, Hirsch AG, Zacker C, Taylor S, Wood GC, Stewart W. Factors associated with first-fill adherence rates for diabetic medications: a cohort study. J Gen Inter Med 2009;24:233-7.
21. Shah NR, Hirsch AG, Zacker C, et al. Predictors of first-fill adherence for patients with hypertension. Am J Hypertens 2009;22:392-6.
22. Bambauer KZ, Soumerai SB, Adams AS, Zhang F, Ross-Degnan D. Provider and patient characteristics associated with antidepressant nonadherence: the impact of provider specialty. J Clin Psychiatry 2007;68:867-73. (Pubitemid 47015485)
23. Kennedy J, Tuleu I, Mackay K. Unfilled prescriptions of medicare beneficiaries: prevalence, reasons, and types of medicines prescribed. J Mana Care Pharm 2008;14:553-60.
24. Fairman KA, Teitelbaum F, Drevets WC, Engquist G, Kreisman JJ, Norusis MJ. Course of antidepressant treatment with tricyclic versus selective serotonin reuptake inhibitor agents: a comparison in managed care and fee-for-service environments. Am J Manage Care 1997;3:453-65. (Pubitemid 127529825)
25. Moisan J, Gregoire JP. Patterns of discontinuation of atypical antipsychotics in the province of Quebec: a retrospective prescription claims database analysis. Clin Ther 2010;2 suppl 1:S21-31.
26. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002;63:892-909. (Pubitemid 35231730)
27. Arango C, Bombin I, Gonzalez-Salvador T, Garcia-Cabeza I, Bobes J. Randomised clinical trial comparing oral versus depot formulations of zuclopenthixol in patients with schizophrenia and previous violence. Eur Psychiat 2006;21:34-40. (Pubitemid 43245596)
28. Zhang M, Wang M, Li J, Phillips MR. Randomised-control trial of family intervention for 78 first-episode male schizophrenic patients. An 18-month study in Suzhou, Jiangsu. Brit J Psychiat 1994;165:96-102. (Pubitemid 24259374)
29. Adams J, Scott J. Predicting medication adherence in severe mental disorders. Acta Psychiatr Scand 2000;101:119-24. (Pubitemid 30084422)
30. Gallefoss E, Bakke PS, Kjaersgaard P. Quality of life assessment after patient education in a randomized controlled study on asthma and chronic obstructive pulmonary disease. Am J Resp Crit Care Medicine 1999;159:812-7. (Pubitemid 29137778)
31. Kamali M, Kelly BD, Clarke M, et al. A prospective evaluation of adherence to medication in first episode schizophrenia. Eur Psychiat 2006;21:29-33. (Pubitemid 43243050)
32. Duncan JC, Rogers R. Medication compliance in patients with chronic schizophrenia: implications for the community management of mentally disordered offenders. J Forensic Sci 1998;43:1133-7. (Pubitemid 28554808)
33. Eaddy M, Grogg A, Locklear J. Assessment of compliance with antipsychotic treatment and resource utilization in a Medicaid population. Clin Ther 2005;27:263-72. (Pubitemid 40462022)
34. Henry A, Batey RG. Enhancing compliance not a prerequisite for effective eradication of Helicobacter pylori: the HelP study. Am J Gastroenterol 1999;94:811-5. (Pubitemid 29124886)
35. Glick ID, Berg PH. Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders. Int Clin Psychopharmacol 2002;1765-8.
36. Samet JH, Horton NJ, Meli S, et al. A randomized controlled trial to enhance antiretroviral therapy adherence in patients with a history of alcohol problems. Antivir Ther 2005;10:83-93. (Pubitemid 40767634)
37. Marquez CE, Casado MJ, Corchado AY, et al. Efficacy of an intervention to improve treatment compliance in hyperlipidemias. Atencion Primaria 2004;33:443-50.
38. Cooper C, Bebbington P, King M, et al. Why people do not take their psychotropic drugs as prescribed: results of the 2000 National Psychiatric Morbidity Survey. Acta Psychiatr Scand 2007;116:47-53. (Pubitemid 46889774)
39. Schroeder K, Fahey T, Hollinghurst S, Peters TJ. Nurse-led adherence support in hypertension: a randomized controlled trial. Fam Pract 2005;22:144-51. (Pubitemid 40533088)
40. Conte G, Ferrari R, Guarneri L, Calzeroni A, Sacchetti E. Reducing the revolving door phenomenon. Am J Psychiat 1996;153:1512.
41. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophrenia Bull 1997;23:637-51. (Pubitemid 27485972)
42. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995;21:419-29.
43. Weiden P, Glazer W. Assessment and treatment selection for revolving door inpatients with schizophrenia. Psychiatr Q 1997;68:377-92. (Pubitemid 27468948)
44. Coldham EL, Addington J. D. A. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand 2002;106:286-90.
45. Giron M, Gomez-Beneyto M. Relationship between empathic family attitude and relapse in schizophrenia: a 2-year followup prospective study. Schizophr Bull 1998;24:619-27. (Pubitemid 28524630)
46. Robinson DG, Woerner MG, Alvir JM, Bilder RM, Hinrichsen GA, Lieberman JA. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr Res 2002;57:209-19. (Pubitemid 35240023)
47. Agarwal MR, Sharma VK, Kishore Kumar KV, Lowe D. Non-compliance with treatment in patients suffering from schizophrenia: a study to evaluate possible contributing factors. Int J Soc Psychiatry 1998;44:92-106. (Pubitemid 28352140)
48. Kampman O, Laippala P, Vaananen J, et al. Indicators of medication compliance in first-episode psychosis. Psychiatry Res 2002;110:39-48. (Pubitemid 34451095)
49. McCann TV, Boardman G, Clark E. Risk profiles for nonadherence to antipsychotic medications. J Psychiat Ment Health Nurs 2008;15:622-9.
50. American Diabetes Association American Psychiatric Association. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601.
51. Clayton AH, Balon R. The impact of mental illness and psychotropic medications on sexual functioning: the evidence and management. J Sex Med 2009;6:1200-11.
52. Novick D, Haro JM, Bertsch J, Haddad PM. Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia. J Clin Psychopharm 2010;30:531-40.
53. Sameroff AJ, Chandler MJ. Reproductive risk and the continuum of caretaking casualty. In: Horowitz FD, Hetherington M, Scarr-Salapatek S, Siegal G, eds. Review of child development research. Chicago: University of Chicago Press, 1975:187-244.
54. Sameroff AJ, MacKenzie MJ. Research strategies for capturing transactionalmodels of development: The limits of the possible. Dev Psychopathol 2003;15:613-40. (Pubitemid 351480035)
55. Bronfenbrenner U. The ecology of human development. Cambridge: Harvard University Press, 1979.
56. Elliott RA, Shinogle JA, Peele P, Bhosle M, Hughes DA. Understanding medication compliance and persistence from an economics perspective. Value Health 2008;11:600-10. (Pubitemid 352032815)
57. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: Associations with medication and medical utilization and spending and health. JAMA 2007;298:61-9. (Pubitemid 47026771)
58. West JC, Wilk JE, Rae DS, et al. Medicaid prescription drug policies and medication access and continuity: findings from ten states. Psychiatr Serv 2009;60:601-10.
59. Piette JD, Heisler M, Wagner TH. Cost-related medication underuse: do patients with chronic illnesses tell their doctors? Arch Internal Med 2004;164:1749-55. (Pubitemid 39215643)
60. Wilbur K. Resident physician and hospital pharmacist familiarity with patient discharge medication costs. Pharm World Sci 2009;31:195-201.
61. Rogers AS, Miller S, Murphy DA, Tanney M, Fortune T. The TREAT (Therapeutic Regimens Enhancing Adherence in Teens) program: theory and preliminary results. J Adolesc Health 2001;29:30-8. (Pubitemid 32799157)
62. Voruganti LNP, Awad AG. Personal evaluations of transitions in treatment (PETiT): a scale to measure subjective aspects of antipsychotic drug therapy in schizophrenia. Schizophr Res 2002;56:37-46. (Pubitemid 34655466)
63. Voruganti LNP, Awad AG. Is neuroleptic dysphoria a variant of drug-induced extrapyramidal side effects? Can J Psychiat 2004;49:285-9. (Pubitemid 38724632)
64. Voruganti LNP, Awad AG. Neuroleptic dysphoria: towards a new synthesis. Psychpharmacology 2004;171:121-32. (Pubitemid 38134648)
65. Voruganti LNP, Slomka P, Zabel P, et al. Subjective effects of AMPT-induced dopamine depletion in schizophrenia: correlation between dysphoric responses and striatal D2 binding ratios on SPECT imaging. Neuropsychopharmacology 2004;25:642-50. (Pubitemid 32995946)
66. Mizrahi R, Rusjan P, Agid O, et al. Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia. Am J Psychiat 2007;164:630-7. (Pubitemid 46650195)
67. Prochaska JO, Velicer WF, Rossi JS, et al. Stages of change and decisional balance for 12 problem behaviors. Health Psychol 1994;13:39-46.
68. Zolnierek KBH, DiMatteo MR. Physician communication and patient adherence to treatment: a meta-analysis. Med Care 2009;47:826-34.
69. Piette JD, Neisler M, Krein S, Kerr EA. The role of patientphysician trust in moderating medication nonadherence due to cost pressures. Arch Intern Med 2005;165:1749-55. (Pubitemid 41138963)
70. Charles C, Gafni A, Whelan T. Shared decision-making in the medical encounter: what does it mean? (Or it takes at least two to tango). Soc Sci Med 1997;44:681-92. (Pubitemid 27067502)
71. Kravitz RL, Epstein RM, Feldman MD, et al. Influence of patients requests for direct-to-consumer advertised antidepressants. JAMA 2005;293:1995-2002. (Pubitemid 40570893)
72. Clatworthy J, Bowskill R, Parham R, Rank T, Scott J, Horne R. Understanding medication non-adherence in bipolar disorders using a necessity-concerns framework. J Affect Disord 2009;116:51-5.
73. Aikens JE, Nease DE, Nau DP, Klinkman MS, Schwenk TL. Adherence tomaintenance-phase antidepressant medication as a function of patient beliefs about medication. Ann Fam Med 2005;2:23-30. (Pubitemid 40203944)
74. Libby AM, Brent DA, Morrato EH, Orton HD, Allen R, Valuck RJ. Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs. Am J Psychiat 2003;160:973-8; 2007;164:884-91.
75. Rudd MD, Cordero L, Bryan CJ. What every psychologist should know about the Food and Drug Administrations black box warning label for antidepressants. Prof Psychol Res Pract 2009;40:321-6.
76. Marshall RD, Posner K, Greenhill L. Risk perception research and the black box warning for SSRIs in children. J Am Acad Child Adol Psychiat 2006;45:765. (Pubitemid 43932898)
77. Slovic P, Finucane ML, Peters E, MacGregor DG. Risk as analysis and risk as feelings: some thoughts about affect, reason, risk, and rationality. Risk Analysis 2004;24:311-22. (Pubitemid 38620129)
78. Busch SH, Barry CL. Pediatric antidepressant use after the black-box warning. Health Affairs 2009;28:724-33.
79. Gibbons RD, Hur K, Bhaumik DK, Mann JJ. The relationship between antidepressant prescription rates and rate of early adolescent suicide. Am J Psychiat 2006;163:1898-904. (Pubitemid 44807781)
80. Bridge JA, Greenhouse JB, Weldon AH, Campo JV, Kelleher KJ. Suicide trends among youths aged 10 to 19 years in the United States, 1996-2005. JAMA 2008;300:1025-8.
81. Lambert M, Conus P, Cotton S, Robinson J, McGorry PD, Schimmelmann BG. Prevalence, predictors, and consequences of long-term refusal of antipsychotic treatment in first-episode psychosis. J Clin Psychopharmacol 2010;30:565-72.
82. Mohammed S, Rosenheck R, McEvoy J, Swartz M, Stroup S, Lieberman JA. Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. Schizophr Bull 2009;35:336-46.
83. Young DA, Davila R, Scher H. Unawareness of illness and neuropsychological performance in chronic schizophrenia. Schizophr Res 1993;10:117-24. (Pubitemid 23273364)
84. Weiler MA, Fleisher MH, McArthur-Campbell D. Insight and symptom change in schizophrenia and other disorders. Schizophr Res 2000;45:29-36.
85. Karp DA. Is it me or my meds? Living with antidepressants. Cambridge: Harvard University Press, 2006.
86. Rogers A, Day JC, Williams B, et al. The meaning and management of neuroleptic medication: a study of patients with a diagnosis of schizophrenia. Soc Sci Med 1998;47:1313-23. (Pubitemid 28444745)
87. Rosenfield PJ. Poison or cure: meanings of medication in schizophrenia. J Am Acad Psychoanal Dyn Psychiatry 2007;35:189-201. (Pubitemid 47173882)
88. Tutter A. Medication as object. J Am Psychoanal Assoc 2006;54:781-804. (Pubitemid 44448892)
89. Favre S, HugueletMA, Vogel S, GonzalezMA. Neuroleptic compliance in a cohort of first episode schizophrenics: a naturalistic study. Eur J Psychiat 1997;11:35-42. (Pubitemid 27204841)
90. Ramana R, Paykel ES, Surtees PG,Melzer D,Mehta MA.Medication received by patients with depression following the acute episode: adequacy and relation to outcome. Brit J Psychiatry 1999;174:128-34. (Pubitemid 29089286)
91. Scott J, Pope M. Self-reported adherence to treatment with mood stabilizers, plasma levels, and psychiatric hospitalization. Am J Psychiatry 2002;159:1927-9. (Pubitemid 35283261)
92. Sohler NL, Walkup J, McAlpine D, Boyer C, Olfson M. Antipsychotic dosage at hospital discharge and outcomes among persons with schizophrenia. Psychiatr Serv 2003;54:1258-63 [see comment]. (Pubitemid 37055988)